BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Drug Interaction & Methadone & Buprenorphine

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: DCV 3DAA FDC
Drug: Methadone
Drug: BMS-791325
Drug: Buprenorphine
Drug: Naloxone

First Posted Date: 2014-01-27

Last Posted Date: 2014-06-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT02045693

Locations: 🇺🇸
Cri Lifetree, Philadelphia, Pennsylvania, United States
🇺🇸
Anaheim Clinical Trials Llc, Anaheim, California, United States
🇺🇸
Lifetree Clinical Research, Salt Lake City, Utah, United States

Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: Cocktail
Drug: DCV 3DAA FDC
Drug: BMS-791325

First Posted Date: 2014-01-27

Last Posted Date: 2014-06-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT02045966

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Phase 3

Completed

Conditions: Stage IV or Recurrent Non-Small Cell Lung Cancer

Interventions: Biological: Nivolumab
Drug: Gemcitabine
Drug: Cisplatin
Drug: Carboplatin
Drug: Paclitaxel
Drug: Pemetrexed

First Posted Date: 2014-01-22

Last Posted Date: 2023-03-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 541

Registration Number: NCT02041533

Locations: 🇯🇵
Local Institution - 0159, Akashi, Hyogo, Japan
🇺🇸
Southern Cancer Center, Inc., Mobile, Alabama, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 138 locations

Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)

Phase 2

Completed

Conditions: Lymphoma. Non-Hodgkin

Interventions: Drug: Nivolumab

First Posted Date: 2014-01-17

Last Posted Date: 2021-10-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 121

Registration Number: NCT02038933

Locations: 🇬🇧
Local Institution, Sutton, Surrey, United Kingdom
🇫🇷
Hopital Saint Eloi, Montpellier Cedex 05, France
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 10 locations

Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Nivolumab

First Posted Date: 2014-01-17

Last Posted Date: 2022-01-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 116

Registration Number: NCT02038946

Locations: 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇬🇧
Local Institution, Sutton, Surrey, United Kingdom

and more 18 locations

Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept

First Posted Date: 2014-01-16

Last Posted Date: 2018-02-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 153

Registration Number: NCT02037737

Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Apixaban
Dietary Supplement: Boost Plus

First Posted Date: 2014-01-13

Last Posted Date: 2016-06-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 37

Registration Number: NCT02034591

Locations: 🇺🇸
Healthcare Discoveries, LLC D/B/A Icon Development Solutions, San Antonio, Texas, United States

Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Apixaban

First Posted Date: 2014-01-13

Last Posted Date: 2016-08-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 48

Registration Number: NCT02034565

Locations: 🇺🇸
Mds Pharma Services, Neptune, New Jersey, United States

Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Apixaban

First Posted Date: 2014-01-13

Last Posted Date: 2016-07-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 75

Registration Number: NCT02034578

Locations: 🇺🇸
Parexel Baltimore Early Phase Clinical Unit, Baltimore, Maryland, United States

Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: Daclatasvir
Drug: Sofosbuvir

First Posted Date: 2014-01-10

Last Posted Date: 2015-10-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 173

Registration Number: NCT02032901

Locations: 🇺🇸
Scripps Clinic, La Jolla, California, United States
🇺🇸
University of Florida Hepatology Research, Gainesville, Florida, United States
🇺🇸
Midland Florida Clinical Research Center, LLC, Deland, Florida, United States

and more 28 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy